Skip to main content
TPST logo

Tempest Therapeutics, Inc.

TPSTNASDAQHealthcareBiotechnology

$0.51Today:- (-)1Y −94.94%

As of Oct 26, 2026 close

Market cap
$7.77M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.57$11.13
Volume (live)
-
Avg. volume (3M)
5.22M

Tempest Therapeutics (TPST) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Tempest Therapeutics used $26.82M of cash in operating activities. Free cash flow was −$26.82M.

Tempest Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Tempest Therapeutics, Inc. (TPST) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-26.26-41.84-29.49-35.71-28.30-19.21-44.57-27.19-84.58
Depreciation & Amortization0.270.390.380.640.370.341.050.031.65
Stock Based Compensation3.125.302.551.561.110.450.001.436.89
Change in Working Capital-5.131.61-2.680.87-0.61-1.07-2.051.04-1.84
Change in Accounts Payable-1.411.61-0.260.00-0.21-0.57-0.470.32-1.45
Change in Other Working Capital-3.721.511.880.87-0.40-0.50-1.580.72-0.39
Other Operating Activities1.191.511.881.571.480.474.350.0066.05
Net Cash from Operating Activities-26.82-33.03-27.36-31.07-25.96-19.02-41.22-23.65-20.34
Investing Activities
Capital Expenditures0.00-0.44-0.17-0.56-0.14-0.05-0.40-0.040.00
Acquisitions0.000.000.000.000.000.000.00-1.330.00
Purchases of Investments0.000.000.000.000.000.000.000.00-68.86
Sales/Maturities of Investments0.000.000.000.000.000.004.392.4987.79
Other Investing Activities0.000.000.000.000.040.040.000.00-1.45
Net Cash from Investing Activities0.00-0.44-0.17-0.56-0.10-0.013.991.120.46
Financing Activities
Debt Repayment-6.43-4.400.00-4.7415.000.00-0.206.48-4.47
Common Stock Issued10.6928.5935.608.8633.430.0027.1538.760.00
Other Financing Activities0.000.310.007.2810.6434.600.0033.320.00
Net Cash from Financing Activities4.2624.5035.6011.4059.0634.6026.9478.55-4.46
Summary
Effect of Forex Changes on Cash0.000.000.000.000.000.000.470.120.00
Net Change in Cash-22.56-8.968.08-20.2333.0115.58-9.8255.71-26.31
Cash at Beginning of Period30.7139.6731.6051.8318.823.2473.3317.6243.93
Cash at End of Period8.1530.7139.6731.6051.8318.8263.5173.3317.62
Free Cash Flow-26.82-33.46-27.53-31.63-26.09-19.07-41.62-23.68-20.34
Supplemental Disclosures
Interest Paid-1.181.251.540.95----
Income Taxes Paid-0.050.190.02-----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Tempest Therapeutics Cash Flow

What is Tempest Therapeutics's free cash flow?

Tempest Therapeutics had negative free cash flow of $26.82M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Tempest Therapeutics pay dividends or buy back shares?

Tempest Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition